Prognostic Value of MicroRNA-182 in Cancers: A Meta-AnalysisReport as inadecuate




Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis - Download this document for free, or read online. Document in PDF available to download.

Disease Markers - Volume 2015 2015, Article ID 482146, 8 pages -

Review Article

Department of Hematology Key Department of Jiangsu Medicine, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China

Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing 210009, China

Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China

Department of Pathology, Medical School, Southeast University, Nanjing 210009, China

Received 13 January 2015; Accepted 14 April 2015

Academic Editor: Andreas Pich

Copyright © 2015 Fei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. MicroRNA-182 miR-182 exhibits altered expression in various cancers. The aim of this study was to investigate the predictive value of miR-182 expression for cancer patient survival. Methods. Eligible studies were identified through multiple search strategies, and the hazard ratios HRs for patient outcomes were extracted and estimated. A meta-analysis was performed to evaluate the prognostic value of miR-182. Results. In total, 14 studies were included. A high miR-182 expression level predicted a worse outcome with a pooled HR of 2.18 95% CI: 1.53–3.11 in ten studies related to overall survival OS, especially in Chinese populations. The results of seven studies evaluating disease-free survival-relapse-free survival-recurrence-free interval-disease-specific survival DFS-RFS-RFI-DSS produced a pooled HR of 1.77 95% CI: 0.91–3.43, which was not statistically significant; however, the trend was positive. When disregarding the DSS from one study, the expression of miR-182 was significantly correlated with DFS-RFS-RFI pooled HR = 2.52, 95% CI: 1.67–3.79. Conclusions. High miR-182 expression is associated with poor OS and DFS-RFS-RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed.





Author: Fei Wang, Shanliang Zhong, Haijun Zhang, Wei Zhang, Hongming Zhang, Xue Wu, and Baoan Chen

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents